Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Shanghai ZJ Bio-Tech CoSHSE:688317 +0.63%56 Equity-to-Asset is 0.89 as of Mar. 2026, which is 2% below its 10-year median of 0.91. GuruFocus rates SHSE:688317 with a GF Score™ of 56/100 and a GF Value™ of ¥9.77 (Significantly Overvalued). The stock has 2 warning signs investors should review. Among 852 Medical Devices & Instruments companies, Shanghai ZJ Bio-Tech Co ranks better than 91.31% on this metric.
The historical rank and industry rank for Shanghai ZJ Bio-Tech Co's Equity-to-Asset or its related term are showing as below:
SHSE:688317'
s Equity-to-Asset Range Over the Past 10 Years
Min: 0.77 Med: 0.91 Max: 0.96
Current: 0.89
During the past 13 years, the highest Equity to Asset Ratio of Shanghai ZJ Bio-Tech Co was 0.96. The lowest was 0.77. And the median was 0.91.
SHSE:688317's Equity-to-Asset is ranked better than 91.31% of 852
companies
in the Medical Devices & Instruments industry
Industry Median: 0.645
vs SHSE:688317: 0.89
Shanghai ZJ Bio-Tech Co (SHSE:688317) Equity-to-Asset Explanation
Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.
For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.
Shanghai ZJ Bio-Tech Co Equity-to-Asset Related Terms
Shanghai ZJ Bio-Tech Co Equity-to-Asset Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SHSE:688317 vs ABT, SYK, MDT: Equity-to-Asset Comparison
For the Medical Devices subindustry, Shanghai ZJ Bio-Tech Co's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Shanghai ZJ Bio-Tech Co Equity-to-Asset vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Shanghai ZJ Bio-Tech Co's Equity-to-Asset distribution charts can be found below:
* The bar in red indicates where Shanghai ZJ Bio-Tech Co's Equity-to-Asset falls into.
Shanghai ZJ Bio-Tech Co Equity-to-Asset Calculation
Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.
Shanghai ZJ Bio-Tech Co's Equity to Asset Ratio for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Shanghai ZJ Bio-Tech Co (SHSE:688317) has a Equity-to-Asset of 0.89 as of Mar. 2026. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Shanghai ZJ Bio-Tech Co and its competitors. This is near median its historical median of 0.91. Over the past decade, Shanghai ZJ Bio-Tech Co's Equity-to-Asset has ranged from 0.77 to 0.96. According to the industry distribution chart, Shanghai ZJ Bio-Tech Co ranks #74 out of 852 companies in the Medical Devices & Instruments industry, placing it in the top 8.7%.
Is Shanghai ZJ Bio-Tech Co's Equity-to-Asset too high?
Shanghai ZJ Bio-Tech Co's current Equity-to-Asset of 0.89 is near median its 10-year median of 0.91. Over the past 10 years, this metric has ranged from a low of 0.77 to a high of 0.96. The Medical Devices & Instruments industry median Equity-to-Asset is 0.65. Shanghai ZJ Bio-Tech Co's value of 0.89 is 38% above this industry median. Based on the distribution chart, Shanghai ZJ Bio-Tech Co ranks #74 out of 852 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Shanghai ZJ Bio-Tech Co has a GF Score™ of 56/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Shanghai ZJ Bio-Tech Co's Equity-to-Asset compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Shanghai ZJ Bio-Tech Co ranks #74 out of 852 companies for Equity-to-Asset. This places Shanghai ZJ Bio-Tech Co in the top 9% of its industry — outperforming the majority of peers. The industry median Equity-to-Asset is 0.65. Shanghai ZJ Bio-Tech Co's value of 0.89 is 38% above this benchmark. Historically, Shanghai ZJ Bio-Tech Co's own Equity-to-Asset has ranged from 0.77 to 0.96 over the past decade. While the company's 10-year median is 0.91 vs. the industry median of 0.65, Shanghai ZJ Bio-Tech Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Equity-to-Asset for a Medical Devices & Instruments company?
The median Equity-to-Asset among Medical Devices & Instruments companies is 0.65, based on 852 companies in the industry. Companies in the top quartile (top 25%) have a Equity-to-Asset significantly above this median, while those in the bottom quartile fall well below. However, Equity-to-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Shanghai ZJ Bio-Tech Co's current Equity-to-Asset of 0.89 is 38% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Equity-to-Asset mean?
A high Equity-to-Asset can signal that a stock is expensive relative to its fundamentals. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Shanghai ZJ Bio-Tech Co and its competitors. For the Medical Devices & Instruments industry, the median Equity-to-Asset is 0.65 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Shanghai ZJ Bio-Tech Co's current Equity-to-Asset is 0.89, which is near median its own 10-year median of 0.91. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Shanghai ZJ Bio-Tech Co stock overvalued right now?
Based on GuruFocus' analysis, Shanghai ZJ Bio-Tech Co (SHSE:688317) is currently considered Significantly Overvalued. The stock's GF Value™ is ¥9.77, compared to a current price of ¥15.94 — trading 63.2% above its estimated fair value. The current Equity-to-Asset is 0.89, which is near median its 10-year median of 0.91 and 38% above the Medical Devices & Instruments industry median of 0.65. Shanghai ZJ Bio-Tech Co's overall GF Score™ is 56/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Equity-to-Asset calculated?
Equity-to-Asset is calculated from a company's financial statements. For Shanghai ZJ Bio-Tech Co (SHSE:688317), the current Equity-to-Asset is 0.89 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Shanghai ZJ Bio-Tech Co (SHSE:688317) Overvalued in 2026?
Based on GuruFocus' analysis, Shanghai ZJ Bio-Tech Co stock appears to be overvalued.
The current stock price of ¥15.94 is trading 63.2% above its estimated GF Value™ of ¥9.77.
GuruFocus considers Shanghai ZJ Bio-Tech Co to be Significantly Overvalued.
Key valuation signals for SHSE:688317:
Equity-to-Asset: 0.89 (near median its 10-year median of 0.91)
GF Value™: ¥9.77 vs. price of ¥15.94 (63.2% above fair value)
Industry Position: 38% above the Medical Devices & Instruments median (#74 of 852)
No single metric tells the full story. See the SHSE:688317 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Shanghai ZJ Bio-Tech Co Ltd is engaged in research and development, production and sales of genetic diagnostic reagents and instruments and equipment. The rapid real-time fluorescent PCR diagnostic test reagents developed by the company are mainly used in clinical medicine, public health emergencies, entry-exit inspection and quarantine, food inspection, animal husbandry, aquaculture and other fields.
56GF Score
Get the complete analysis for SHSE:688317
Equity-to-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:688317 has been successfully added to your 
